Lenalidomide induced secondary acute lymphoblastic leukemia in a multiple myeloma patient: a case-report.
Khan, Dr Saqib Raza Tariq, Dr Muhammad Fayyaz, Dr Sidra Malik Soomar, Salman Muhammad Moosajee, Dr Munira
Khan, Dr Saqib Raza
Tariq, Dr Muhammad
Fayyaz, Dr Sidra Malik
Soomar, Salman Muhammad
Moosajee, Dr Munira
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-04-13
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
enalidomide mechanism of action has been shown to modulate the different components of the immune system. A 68-year-old lady presented to us with severe backache and was then diagnosed with MM. Lenalidomide started as per protocol along with dexamethasone. Later, she presented with complaints of generalized weakness and her workup showed significant blast cells with Pan-B-cell markers consistent with secondary B-ALL. The reported incidence of secondary Acute Lymphocytic Leukemia is 2.3%. The development of more aggressive neoplasm in a patient with prior malignancy dictates a poor outcome and hence such patients should be enrolled in a clinical trial whenever available.
Citation
Khan DSR, Tariq DM, Fayyaz DSM, Soomar SM, Moosajee DM. Lenalidomide induced secondary Acute Lymphoblastic Leukemia in a Multiple Myeloma patient: A case-report. Leuk Res Rep. 2022 Apr 13;17:100315. doi: 10.1016/j.lrr.2022.100315
Type
Article